Stock Market Reviews

ERAS (Erasca, Inc.) News

Get the latest news, insights, and market updates on ERAS (Erasca, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
  ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer
  Apr 29, 2025 - $ERAS
• Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?
  We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Erasca Inc. (NASDAQ:ERAS) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]
  Apr 16, 2025 - $ERAS
• Erasca Slides As Insider Purchases Lose Another US$84k
  Insiders who bought US$181.9k worth of Erasca, Inc.'s ( NASDAQ:ERAS ) stock at an average buy price of US$2.27 over the...
  Apr 8, 2025 - $ERAS
• Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
  Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-d
  Mar 25, 2025 - $ERAS